

Special Issue

Effects of Pharmaceutical Intervention on Cardiovascular Risk

Message from the Guest Editors

The current approach to the prevention of cardiovascular diseases includes the promotion of a healthy and physically active lifestyle as well as the administration of drugs for treating cardiovascular risk factors such as hypertension, hypercholesterolemia, or diabetes. Risk factors are often poorly treated and therapeutic goals are often disregarded, even in patients considered to be at high cardiovascular risk. There is, therefore, a need to develop new drugs and optimize the use of medications currently available. At the same time, it is necessary to develop therapeutic strategies suited to the patient's risk profile, with the aim of pursuing an increasingly personalized approach, avoiding overtreatments, and minimizing drug-related side effects.

This Special Issue welcomes manuscripts focused on (1) investigating the effects of new drugs and new treatment strategies on cardiovascular risk factors; (2) optimizing the pharmacological management of patients belonging to different risk categories; and (3) assessing patients' adherence to primary prevention drugs and studying strategies for improving adherence to treatments.

Guest Editors

Dr. Giuseppe Marazzi

Cardiology Rehabilitation Unit, IRCCS San Raffaele, 00163 Rome, Italy

Prof. Dr. Giuseppe Caminiti

1. Department of Human Science and Promotion of Quality of Life, San Raffaele Open University, 00163 Rome, Italy

2. Cardiovascular Unit, San Raffaele IRCCS, 00163 Rome, Italy

Deadline for manuscript submissions

closed (30 November 2025)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/213155

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).